CN113439083A - 二芳基硫代乙内酰脲化合物结晶 - Google Patents

二芳基硫代乙内酰脲化合物结晶 Download PDF

Info

Publication number
CN113439083A
CN113439083A CN202080011977.7A CN202080011977A CN113439083A CN 113439083 A CN113439083 A CN 113439083A CN 202080011977 A CN202080011977 A CN 202080011977A CN 113439083 A CN113439083 A CN 113439083A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystal
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080011977.7A
Other languages
English (en)
Other versions
CN113439083B (zh
Inventor
沈春莉
陈胜林
王廷
刘飞
田心
郭玉莹
张琳
吴家虎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113439083A publication Critical patent/CN113439083A/zh
Application granted granted Critical
Publication of CN113439083B publication Critical patent/CN113439083B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本申请属于医药领域，具体而言涉及具有以下式(I)结构的二芳基硫代乙内酰脲化合物的结晶、其制备方法以及其在制备治疗雄激素介导的相关疾病的药物的用途。
Figure DDA0003189499360000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080011977.7A 2019-02-01 2020-01-22 二芳基硫代乙内酰脲化合物结晶 Active CN113439083B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910104953 2019-02-01
CN2019101049535 2019-02-01
PCT/CN2020/073821 WO2020156448A1 (zh) 2019-02-01 2020-01-22 二芳基硫代乙内酰脲化合物结晶

Publications (2)

Publication Number Publication Date
CN113439083A true CN113439083A (zh) 2021-09-24
CN113439083B CN113439083B (zh) 2023-01-24

Family

ID=71840904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080011977.7A Active CN113439083B (zh) 2019-02-01 2020-01-22 二芳基硫代乙内酰脲化合物结晶

Country Status (12)

Country Link
US (1) US20220009925A1 (zh)
EP (1) EP3919493A4 (zh)
JP (1) JP7464613B2 (zh)
KR (1) KR20210124333A (zh)
CN (1) CN113439083B (zh)
AU (1) AU2020214494A1 (zh)
BR (1) BR112021015122A2 (zh)
CA (1) CA3128074A1 (zh)
IL (1) IL285219A (zh)
MX (1) MX2021009170A (zh)
SG (1) SG11202108300VA (zh)
WO (1) WO2020156448A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563311A (zh) 2017-08-07 2021-10-29 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
CN114929702A (zh) * 2020-01-19 2022-08-19 正大天晴药业集团股份有限公司 作为ar拮抗剂的二芳基硫代乙内酰脲化合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103804358A (zh) * 2012-11-14 2014-05-21 上海医药集团股份有限公司 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
CN104105690A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 作为雄激素受体拮抗剂的环状尿素衍生物
CN104341352A (zh) * 2013-08-09 2015-02-11 南京衡杰生物科技有限公司 作为雄激素受体拮抗剂的二芳基乙内酰脲化合物及其应用
CN104341396A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
CN104341342A (zh) * 2014-10-23 2015-02-11 中国电子科技集团公司第四十六研究所 一种高产率、高纯度的dast源粉合成工艺
CN106146474A (zh) * 2015-04-24 2016-11-23 成都贝斯凯瑞生物科技有限公司 硫代咪唑二酮和咪唑二酮类化合物及其用途
WO2018009678A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563311A (zh) * 2017-08-07 2021-10-29 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104105690A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 作为雄激素受体拮抗剂的环状尿素衍生物
CN103804358A (zh) * 2012-11-14 2014-05-21 上海医药集团股份有限公司 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
CN104341396A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
CN104341352A (zh) * 2013-08-09 2015-02-11 南京衡杰生物科技有限公司 作为雄激素受体拮抗剂的二芳基乙内酰脲化合物及其应用
CN104341342A (zh) * 2014-10-23 2015-02-11 中国电子科技集团公司第四十六研究所 一种高产率、高纯度的dast源粉合成工艺
CN106146474A (zh) * 2015-04-24 2016-11-23 成都贝斯凯瑞生物科技有限公司 硫代咪唑二酮和咪唑二酮类化合物及其用途
WO2018009678A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists

Also Published As

Publication number Publication date
CN113439083B (zh) 2023-01-24
CA3128074A1 (en) 2020-08-06
JP7464613B2 (ja) 2024-04-09
IL285219A (en) 2021-09-30
AU2020214494A1 (en) 2021-09-16
BR112021015122A2 (pt) 2021-09-28
SG11202108300VA (en) 2021-08-30
WO2020156448A1 (zh) 2020-08-06
JP2022518605A (ja) 2022-03-15
US20220009925A1 (en) 2022-01-13
EP3919493A1 (en) 2021-12-08
EP3919493A4 (en) 2022-11-16
KR20210124333A (ko) 2021-10-14
MX2021009170A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
JP7042812B2 (ja) トリアゾロピリミジン化合物の結晶形態
EP2949647B1 (en) Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same
EP2272850B1 (en) Process for purifying staurosporine
CN113439083B (zh) 二芳基硫代乙内酰脲化合物结晶
WO2020132785A1 (en) Novel salts of selective estrogen receptor degraders
EP3322704B1 (en) Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
RU2810214C2 (ru) Кристалл диарилтиогидантоинового соединения
BRPI0710691A2 (pt) processo para a preparação de éster 2-[4-(4-flúor-2-metil-1h-indol-5-ilóxi)-5-metilpirrolo[2, 1-f][1,2,4]-triazin-6-ilóxil]-1-metiletìlico de ácido [(1r)], 2s]-2-aminopropiÈnico
CN113045554A (zh) 一种非索替尼晶型及其制备方法
CN112888690A (zh) 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途
WO2021104186A1 (en) Novel salts of indoleamine 2,3-dioxygenase inhibitors
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
CN112334473B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
CN112851741A (zh) 一种取代的甾体类化合物及其应用
WO2006121857A2 (en) Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
EP1979357A1 (en) Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant